



Policy Updates - Fourth Quarter 2023

NEW DRUG SPECIFIC POLICIES *Effective 1/1/2024*

Adzyna (ADAMTS13, recombinant-krhn)	Litfulo (ritlecitinib)	Sohonos (palovarotene) capsules
Agamree (vamorolone)	Loqtorzi (toripalimab-tpzi)	Veopoz (pozelimab-bbfg)
Aphexda (motixafortide)	Ojjaara (momelotinib)	Voquezna (vonoprazan)
Exxua (gepirone)	Pombiliti (cipaglucoisidase alfa-atga) and Opfolda (miglustat)	Xdemvy (lotilaner) ophthalmic solution
Focinvez (fosaprepitant)	Qlosi (pilocarpine hydrochloride) ophthalmic solution 0.4%	Xphozah (tenapanor)
Fruzaqla (fruqintinib)	Rivfloza (nedosiran)	Zilbrysq (zilucoplan subcutaneous injection)
Hepzato (melphalan)		
Lenalidomide		

EXISTING DRUG SPECIFIC POLICIES WITH CLINICAL CHANGES *Effective 1/1/2024*

Austedo and Austedo XR	Ilaris	Sodium Phenylbutyrate (Applies to Buphenyl, Olpruva and Pheburane) <i>(effective 3/1/24)</i>
Auvelity	Imjudo	Tafinlar
Biological Drugs for Auto Immune Diseases - In Office Administration	Ingrezza	Tibsovo
Biological Drugs for Auto Immune Diseases Self-Administered	Injectable Medications for the Sole purpose of Inducing Pregnancy	Turalio
Bosulif	Jynarque	Tysabri (natalizumab) and Tyruko (natalizumab-sztn)
Botulinum Toxin	Mekinist	Tzield
Daybue	Prolia	Vabysmo
Eylea and Eylea HD (aflibercept injection)	Ravicti (glycerol phenylbutyrate) oral liquid <i>(effective 3/1/24)</i>	Votrient (pazopanib) tablets
Gender Dysphoria Treatment – Commercial Plans	Reblozyl	Voxzogo (vosoritide)
	Rozlytrek	Weight Loss Medications

EXISTING DRUG SPECIFIC POLICIES WITH ADMINISTRATIVE CHANGES *Effective 1/1/2024*

Abilify Maintena	Filgrastim - State Plans (Applies to Granix, Nivestym, Neupogen, Releuko and Zarxio)	In Vitro Fertilization
Aubagio	Gavreto	Inrebic
Beyfortus	Imcivree	Intradialytic Parenteral nutrition (IDPN)
Cinqair		Invega Hafyera

Invega Sustenna	Nucala	Synagis
Ketoconazole tablets	Repository Corticotropin Injection	Takhzyro
Mavenclad	Rolvedon	Trokendi XR
Mavyret – Child Health Plus	Scemblix	Vanflyta
Mirvaso Gel	Solesta	Velettri
Mozobil	Somatuline Depot	Xenpozyme
Novantrone		Xolair

EXISTING DRUG SPECIFIC POLICIES WITH ADMINISTRATIVE CHANGES DUE TO MEDICAID CARVE-OUT

Abiraterone acetate	Exservan	Penicillamine
Accrufer	Eysuvis	Perforomist and Brovana
Addyi	Firazyr	Pretomanid Tablets
Aklief	Furoscix	Qbrexza
Alinia	Galafold	Relyvrio
Amzeeq	Gocovri	Reyvow
Apokyn	Harvoni	Simvastatin High Dose Policy
Balversa	Kuvan	Sovaldi
Benznidazole	Lytgobi	Sprix
Bronchitol	Movantik	Subutex
Brukinsa	Nefazodone	Sunitinib
Copiktra	Nimodipine	Syprine
Cysteamine Ophthalmic Drops (Applies to Cystadrops and Cystaran)	Nubeqa	Tafamidis
Desoximetasone 0.05% cream	Omlonti	Talicia
Diacomit	Opioid Prescribing Limit	Tavneos
Dificid	Orally Disintegrating Tablet (ODT) Policy	Tecfidera
Dronabinol (Applies to Marinol and Syndros)	Oravig Step Therapy	Thiola and Thiola EC
Emend	Orilissa	Tykerb
Epclusa	Orladeyo	Vosevi
Exkivity	Oxbryta	Vumerity
	Oxervate	Vyleesi
		Wakix

Xatmep	Xenleta Oral Tablets	Zokinvy
Xcopri	Zepatier	

EXISTING DRUG SPECIFIC POLICIES REVIEW ONLY/NO CHANGES

Adakveo	Fluocinolone Ophthalmic implant	Qutenza
Aduhelm FEHB	Gelclair	Recarbrio
Aduhelm State Products	Givlaari	Rexulti
Aldurazyme	GnRH Analog Policy for Central Precocious Puberty	Rituximab
Beovu	Healthy New York Sexual or Erectile Dysfunction Medication Coverage	Scenesse
Calcitonin Gene Related Peptide (CGRP) Antagonists for Prophylaxis – Child Health Plus	Kalydeco	Soliris
Clomiphene Citrate	Kanuma	Spevigo
Continuous glucose monitors and supplies - Medicare	Livmarli	Spinraza
Cotempla XR ODT	Mavyret	Subcutaneous Immunoglobulins (SCIG)
Cyclosporine Ophthalmic Drop (applies to Cequa, Restasis and Vevye)	Mydayis	Sustol
Dalvance	Non-sedating Antihistamine Policy	Tecvayli
Descovy	Nulojix	Teriparatide
Eraxis	Onpattro	Trikafta
Fabrazyme	Oxlumo	Tygacil
Fetroja	Pedmark	Vabomere
	Prescriber Specialty Exception Policy	Xerava
		Xipere
		Xpovio
		Zemdri

EXISTING ADMINISTRATIVE POLICIES WITH CHANGES

Compounding Drug Products	Exception Policy for Non Formulary Drugs	Termed provider Prescription Coverage
Drug Formulary Use	Maintenance Drug Policy	

EXISTING ADMINISTRATIVE POLICIES REVIEW ONLY/NO CHANGES

Improperly Filed Pre-Service Claim Procedure Policy
Pharmacy Department Policy Management

POLICIES TO BE ARCHIVED

Perseris

Piqray

PBD NEW DRUG SPECIFIC POLICIES *Effective 1/1/2024*

Piqray

PBD EXISTING DRUG SPECIFIC POLICIES WITH CLINICAL CHANGES *Effective 1/1/2024*

Xifaxan

Weight Loss Medications

Weight Loss Medications for the Labor-Management Healthcare Fund

PBD EXISTING DRUG SPECIFIC POLICIES WITH ADMINISTRATIVE CHANGES

Intra-articular Injection of Hyaluronate Products

PBD EXISTING DRUG SPECIFIC POLICIES REVIEW ONLY/NO CHANGES

In Vitro fertilization (IVF) & Fertility Preservation

Magellan RX Management Drug Specific Policies for Expansion *Effective 11/1/2023*

Aflibercept: Eylea®; Eylea® HD (Intravitreal)

Existing Magellan RX Management Drug Specific Custom Policy Updates *Effective 10/1/2023*

Actemra® (tocilizumab) (Subcutaneous)

Cimzia® (certolizumab pegol) (Subcutaneous)

Cosentyx® (secukinumab) (Subcutaneous)

Orencia® (abatacept) (Intravenous/Subcutaneous)

Existing Magellan RX Management Drug Specific Policies w/Clinical Changes **Effective 10/27/23*

Medical PA Only

Aflibercept	Libtayo	Vectibix
Benlysta_IV	Natalizumab	VPRIV
Cerezyme	Saphnelo	Vyvgart_IV
ElELYso	Soliris	Vyvgart_SQ
Factor VIII	Tecentriq	
Keytruda	Ultomiris	

Pharmacy PA Only

Benlysta_SQ	Bosulif	Gavreto
-------------	---------	---------

Lonsurf

Sprycel

Tasigna

PSCE only (effective 10/1/23)

Fosaprepitant IV

Existing Magellan RX Management Drug Specific Policies w/Clinical Changes *Effective 12/1/2023

Medical PA Only

Actemra_IV

HA_Derivatives

Perjeta

Adcetris

Ilaris

Ranibizumab

Beovu

Imfinzi

Reblozyl

Berinert

Infliximab

Rituximab_IV

Bevacizumab_ONCO

Kadcyla

Ruconest

Cimzia

Kalbitor

Simponi_ARIA

Cinryze

Keytruda

Trastuzumab_IV

Cyramza

Lemtrada

Uplizna

Denosumab

Natalizumab

Vabysmo

Darzalex_IV

Ocrevus

Yervoy

Empaveli

Onpattro

Yondelis

Entyvio

Opdivo

Zoledronic_Acid

Erbitux

Paclitaxel Albumin-Bound

Gazyva

Pemetrexed

Pharmacy PA Only

Actemra_SQ

Orladeyo

Tegsedi

Enspryng

Tafamidis

Xalkori

Haegarda

Tafinlar

Mekinist

Takhzyro

Medical/Pharmacy

Fasenra

Stelara

Existing Magellan RX Management Drug Specific Policies w/Clinical Changes *Effective 12/21/2023

Medical PA Only

Entyvio_IV

Monjuvi

SCIG

IVIG

Mozobil

Tocilizumab_IV

Lumoxiti

Poteligeo

Pharmacy PA Only

Bosulif

Braftovi

Brukinsa

Calquence

Caprelsa

Cosentyx

Cotellic

PSCE only *(effective 12/1/23)*

Botox

Firmagon

Erivedge

Imbruvica

Inrebic

Jakafi

Koselugo

Mektovi

Ninlaro

Oncaspar

Rylaze

Pomalyst

Rezurock

Rozlytrek

Stivarga

Tibsovo

Zelboraf